Synlogic posts Q3 net loss of $0.1M, cash $19.4M; evaluating strategic options

SYNLOGIC, INC.

Net loss of $0.1M ($0.01 per share) vs $12.1M ($2.57 loss per share) in Q3 2023.
Cash and cash equivalents of $19.4M as of Sep 30, 2024; no revenue for Q3.
R&D expenses show $0.7M benefit due to clinical trial refund and accrual reversal.
Restructuring charges of $0.3M related to workforce reduction from Synpheny-3 discontinuation.
Retained Lucid Capital Markets to explore strategic alternatives including M&A or business combination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.